Biotech Sector Gains Momentum After Hours: What Traders Should Watch This Week

The biotech and healthcare landscape lit up on November 21, 2025, as extended trading hours revealed significant investor interest across a handful of key players. Multiple companies saw noteworthy price movements, signaling renewed enthusiasm for innovation-driven healthcare solutions and strategic partnerships reshaping the industry.

Innovation at the Forefront: Digital Health and Oncology Collaboration

Butterfly Network, Inc. (BFLY) captured traders’ attention with a robust showing, jumping 6.04% in after-hours trading to reach $2.81—building on an already impressive 14.22% intraday surge. The digital ultrasound innovator is positioning itself front and center by bringing CEO Joseph DeVivo and Interim CFO Megan Carlson to the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida, on December 2, 2025. The fireside chat and investor meetings are designed to spotlight Butterfly’s handheld ultrasound technology and articulate the company’s expansion roadmap. This move keeps the firm up close with institutional investors and signals confidence in upcoming developments.

In the oncology space, Citius Pharmaceuticals Inc. (CTXR) demonstrated considerable strength, climbing 7.90% after hours to $1.23, following a robust 15.15% close at $1.14. The real catalyst here is Citius Oncology’s expanded partnership with Verix, leveraging its AI-driven Tovana platform to accelerate commercialization of LYMPHIR (denileukin diftitox-cxdl)—an FDA-approved immunotherapy targeting cutaneous T-cell lymphoma. With a U.S. market entry slated for Q4 2025, this collaboration positions the company to capture meaningful revenue from a specialized but crucial therapeutic segment.

Pipeline Expansion and Strategic M&A Activity

Tempest Therapeutics, Inc. (TPST) reversed intraday weakness with a 4.86% gain to $3.67 after hours, erasing an earlier 4.89% decline. The catalyst stems from the company’s acquisition of dual-targeting CAR-T programs from Factor Bioscience—a transformative all-stock deal expected to finalize in early 2026. By securing TPST-2003, a CD19/BCMA dual-CAR T cell therapy, Tempest strengthens its oncology pipeline while securing operational funding through mid-2027. This move exemplifies how biotech firms are using strategic M&A to bolster their competitive positioning in the high-stakes cell therapy market.

Technical Moves and Steadier Sentiment

ProQR Therapeutics N.V. (PRQR) added 6.80% in extended trading to $2.20, despite a flat close at $2.06. Absent fresh company-specific developments, the uptick likely reflects technical trading dynamics and broader sector momentum. Similarly, Perrigo Company plc (PRGO), the consumer healthcare player, extended its gains with a 3.97% after-hours move to $13.14, building on a 3.10% close—signaling sustained investor confidence despite the absence of new catalysts on the day.

Smaller players showed mixed conviction: Iterum Therapeutics plc (ITRM) edged up 2.77% to $0.3969 after hours, following a 4.38% intraday pop, while Processa Pharmaceuticals, Inc. (PCSA) managed a modest 1.86% gain to $0.26, struggling against earlier selling pressure that saw the stock drop 7.16% during the regular session.

What This Means for Traders

Friday’s after-hours session underscored a bifurcated biotech market: companies with near-term catalysts—whether clinical, commercial, or M&A-related—captured disproportionate investor firepower, while names lacking immediate news drivers saw more muted activity. For traders watching the sector, the convergence of digital health innovation, oncology breakthroughs, and strategic consolidation suggests the biotech narrative remains intact heading into year-end and beyond.